ACE2 and COVID-19: Using this procedure, we first verified that serum samples from pre–COVID-19 pandemic healthy donors (n = 104; Fig. 1, B and C) did not cross-react (2) and interfere with ACE2-Fc binding to S3-coupled beads, whereas serum from postinfected donors induced a dilution-dependent signal reduction (Fig. 1C).